Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Idiopathic pulmonary fibrosis treatment is a measure to cure lung disease. Idiopathic pulmonary fibrosis is a chronic, progressive, fibrotic, interstitial lung disease. Its lesions are confined to the lungs and often occur in middle-aged and elderly people. Medications used to treat idiopathic pulmonary fibrosis include tyrosinase inhibitors, MAPK inhibitors, and autologous toxin inhibitors according to type.
During the forecast period, the global idiopathic pulmonary fibrosis treatment market will achieve a growth rate of 8.6% CAGR. Regionally, North America will continue to dominate the global idiopathic pulmonary fibrosis treatment market over the next few years due to its high market penetration and rising drug prices.
The increase in the prevalence of idiopathic pulmonary fibrosis and the increase in the elderly population are major drivers of the growth of the idiopathic pulmonary fibrosis treatment market. The increase in smoking directly contributes to the high prevalence of idIopathic pulmonary fibrosis, which stimulates the global market for the treatment of idiopathic pulmonary fibrosis. However, strict government regulatory policies will to some extent limit the growth of the global idiopathic pulmonary fibrosis treatment market.
The report details the trend, potential and market size of Idiopathic Pulmonary Fibrosis Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Idiopathic Pulmonary Fibrosis Treatmentmarket, defines the market attractiveness level of Idiopathic Pulmonary Fibrosis Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Idiopathic Pulmonary Fibrosis Treatment industry, describes the types of Idiopathic Pulmonary Fibrosis Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Idiopathic Pulmonary Fibrosis Treatment market and the development prospects and opportunities of Idiopathic Pulmonary Fibrosis Treatment industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Idiopathic Pulmonary Fibrosis Treatment market in Chapter 13.
By Player:
Boehringer Ingelheim
Amgen
Biogen
Afferent Pharmaceuticals
FibroGen
Prometheus Laboratories
Bristol-Myers Squibb
Baxter
Cipla
By Type:
Tyrosine Inhibitors
MAPK Inhibitors
Autotaxin Inhibitors
By End-User:
Hospital
Clinic
Long-term Care Facilities
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Idiopathic Pulmonary Fibrosis Treatment Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Idiopathic Pulmonary Fibrosis Treatment Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Idiopathic Pulmonary Fibrosis Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Idiopathic Pulmonary Fibrosis Treatment Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Idiopathic Pulmonary Fibrosis Treatment Market Analysis and Outlook to 2022
-
7.1 Global Idiopathic Pulmonary Fibrosis Treatment Consumption (2017-2022)
-
7.2 United States Idiopathic Pulmonary Fibrosis Treatment Consumption (2017-2022)
-
7.3 Europe Idiopathic Pulmonary Fibrosis Treatment Consumption (2017-2022)
-
7.4 China Idiopathic Pulmonary Fibrosis Treatment Consumption (2017-2022)
-
7.5 Japan Idiopathic Pulmonary Fibrosis Treatment Consumption (2017-2022)
-
7.6 India Idiopathic Pulmonary Fibrosis Treatment Consumption (2017-2022)
-
7.7 South Korea Idiopathic Pulmonary Fibrosis Treatment Consumption (2017-2022)
8 Region and Country-wise Idiopathic Pulmonary Fibrosis Treatment Market Analysis and Outlook to 2028
-
8.1 Global Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast (2022-2028)
-
8.2 United States Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast (2022-2028)
-
8.3 Europe Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast (2022-2028)
-
8.4 China Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast (2022-2028)
-
8.5 Japan Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast (2022-2028)
-
8.6 India Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast (2022-2028)
-
8.7 South Korea Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast (2022-2028)
9 Global Idiopathic Pulmonary Fibrosis Treatment Market Outlook by Types and Applications to 2022
-
9.1 Global Idiopathic Pulmonary Fibrosis Treatment Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Tyrosine Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.2 Global MAPK Inhibitors Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Autotaxin Inhibitors Consumption and Growth Rate (2017-2022)
-
9.2 Global Idiopathic Pulmonary Fibrosis Treatment Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Long-term Care Facilities Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Others Consumption and Growth Rate (2017-2022)
10 Global Idiopathic Pulmonary Fibrosis Treatment Market Outlook by Types and Applications to 2028
-
10.1 Global Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Tyrosine Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global MAPK Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Autotaxin Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Long-term Care Facilities Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global Idiopathic Pulmonary Fibrosis Treatment Import and Export Analysis (Top 5 Countries)
-
11.1 Global Idiopathic Pulmonary Fibrosis Treatment Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Idiopathic Pulmonary Fibrosis Treatment Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Idiopathic Pulmonary Fibrosis Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Idiopathic Pulmonary Fibrosis Treatment Market Competitive Analysis
-
14.1 Boehringer Ingelheim
-
14.1.1 Boehringer Ingelheim Company Details
-
14.1.2 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
14.2 Amgen
-
14.2.1 Amgen Company Details
-
14.2.2 Amgen Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Amgen Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
14.3 Biogen
-
14.3.1 Biogen Company Details
-
14.3.2 Biogen Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Biogen Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
14.4 Afferent Pharmaceuticals
-
14.4.1 Afferent Pharmaceuticals Company Details
-
14.4.2 Afferent Pharmaceuticals Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Afferent Pharmaceuticals Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
14.5 FibroGen
-
14.5.1 FibroGen Company Details
-
14.5.2 FibroGen Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 FibroGen Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
14.6 Prometheus Laboratories
-
14.6.1 Prometheus Laboratories Company Details
-
14.6.2 Prometheus Laboratories Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Prometheus Laboratories Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
14.7 Bristol-Myers Squibb
-
14.7.1 Bristol-Myers Squibb Company Details
-
14.7.2 Bristol-Myers Squibb Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Bristol-Myers Squibb Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
14.8 Baxter
-
14.8.1 Baxter Company Details
-
14.8.2 Baxter Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Baxter Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
14.9 Cipla
-
14.9.1 Cipla Company Details
-
14.9.2 Cipla Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Cipla Idiopathic Pulmonary Fibrosis Treatment Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Idiopathic Pulmonary Fibrosis Treatment
-
Figure Idiopathic Pulmonary Fibrosis Treatment Picture
-
Table Global Idiopathic Pulmonary Fibrosis Treatment Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Idiopathic Pulmonary Fibrosis Treatment Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Idiopathic Pulmonary Fibrosis Treatment Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Idiopathic Pulmonary Fibrosis Treatment Consumption by Country (2017-2022)
-
Figure United States Idiopathic Pulmonary Fibrosis Treatment Consumption and Growth Rate (2017-2022)
-
Table Europe Idiopathic Pulmonary Fibrosis Treatment Consumption and Growth Rate (2017-2022)
-
Figure China Idiopathic Pulmonary Fibrosis Treatment Consumption and Growth Rate (2017-2022)
-
Figure Japan Idiopathic Pulmonary Fibrosis Treatment Consumption and Growth Rate (2017-2022)
-
Figure India Idiopathic Pulmonary Fibrosis Treatment Consumption and Growth Rate (2017-2022)
-
Figure South Korea Idiopathic Pulmonary Fibrosis Treatment Consumption and Growth Rate (2017-2022)
-
Figure Global Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast by Country (2022-2028)
-
Figure United States Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Idiopathic Pulmonary Fibrosis Treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Tyrosine Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global MAPK Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Autotaxin Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Hospital Consumption and Growth Rate (2017-2022)
-
Figure Global Clinic Consumption and Growth Rate (2017-2022)
-
Figure Global Long-term Care Facilities Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Tyrosine Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global MAPK Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Autotaxin Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Long-term Care Facilities Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Idiopathic Pulmonary Fibrosis Treatment Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Idiopathic Pulmonary Fibrosis Treatment Export by Region (Top 5 Countries) (2017-2028)
-
Table Boehringer Ingelheim (Foundation Year, Company Profile and etc.)
-
Table Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
Table Amgen (Foundation Year, Company Profile and etc.)
-
Table Amgen Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Amgen Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
Table Biogen (Foundation Year, Company Profile and etc.)
-
Table Biogen Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Biogen Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
Table Afferent Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Afferent Pharmaceuticals Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Afferent Pharmaceuticals Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
Table FibroGen (Foundation Year, Company Profile and etc.)
-
Table FibroGen Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table FibroGen Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
Table Prometheus Laboratories (Foundation Year, Company Profile and etc.)
-
Table Prometheus Laboratories Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Prometheus Laboratories Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)
-
Table Bristol-Myers Squibb Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Bristol-Myers Squibb Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
Table Baxter (Foundation Year, Company Profile and etc.)
-
Table Baxter Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Baxter Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
Table Cipla (Foundation Year, Company Profile and etc.)
-
Table Cipla Idiopathic Pulmonary Fibrosis Treatment Sales, Price, Value and Gross Profit (2017-2022)
-
Table Cipla Idiopathic Pulmonary Fibrosis Treatment Product and Service
-
